1 Evidence for Virus-Mediated Oncogenesis in Bladder Cancers Arising in Solid Organ

- 2 Transplant Recipients
- 3

4 Authors

- 5 Gabriel J Starrett¹, Kelly Yu², Yelena Golubeva³, Petra Lenz³, Mary L Piaskowski¹, David Petersen¹,
- 6 Michael Dean², Ajay Israni⁴, Brenda Y Hernandez⁵, Thomas C Tucker⁶, Iona Cheng⁷, Lou Gonsalves⁸,
- 7 Cyllene R Morris⁹, Shehnaz K Hussain¹⁰, Charles F Lynch¹¹, Reuben S Harris¹², Ludmila Prokunina-
- 8 Olsson², Paul Meltzer¹, Christopher B Buck¹*, and Eric A Engels²*.
- 9

10 Affiliations

- ¹ CCR, NCI, NIH, Bethesda, MD, USA
- 12 ² DCEG, NCI, NIH, Rockville, MD, USA
- 13 ³ Leidos Biomedical Research Inc., Frederick, MD, USA
- ⁴ Department of Medicine, Nephrology Division, Hennepin Healthcare System, University of Minnesota-
- 15 Twin Cities, Minneapolis, MN, USA
- 16 ⁵ University of Hawai'i Cancer Center, Honolulu HI, USA
- ⁶ The Kentucky Cancer Registry, University of Kentucky, Markey Cancer Center, KY, USA
- ⁷ University of California-San Francisco, Department of Epidemiology & Biostatistics, and Helen Diller
- 19 Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
- 20 ⁸ Connecticut Tumor Registry, Connecticut Department of Public Health, Hartford, CT, USA
- ⁹ California Cancer Reporting and Epidemiologic Surveillance Program, UC Davis Comprehensive
- 22 Cancer Center/UC Davis Health, Davis, CA, USA
- ¹⁰ Cedars-Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA,
- 24 USA
- 25 ¹¹ The Iowa Cancer Registry, The University of Iowa, Iowa City, IA, USA
- 26 ¹² Howard Hughes Medical Institute, University of Minnesota-Twin Cities, Minneapolis, MN, USA
- 27 *These authors contributed equally

1	Corresponding author: Gabriel J Starrett, gabe.starrett@nih.gov
2	
3	Author Contributions:
4	GJS, CBB, and EAE interpreted data, conceptualized, and drafted the initial manuscript. GJS performed
5	data analysis, statistics, and generated figures. EAE and KY analyzed and summarized case clinical data.
6	GJS, MLP, and DP extracted nucleic acids and prepared libraries from tumor specimens. MD, PM, LP,
7	and RSH provided key resources and interpreted data. YG performed IHC and PL reviewed and analyzed
8	histology for all specimens. KY, AI, TCT, IC, LG, CRM, CFL, BYH, and SKH coordinated case and
9	specimen identification and acquisition from registry hospitals. All authors read and approved the final
10	manuscript.
11	
12	Competing Interest Statement: RSH is a co-founder, shareholder, and consultant of ApoGen
13	Biotechnologies Inc. The remaining authors have no competing interests to declare.
14	Preprint Servers: MedRXiv, https://www.medrxiv.org/content/10.1101/2021.11.11.21266080v1
15	Keywords: Bladder cancer, polyomavirus, papillomavirus, torque teno virus, solid organ
16	transplant recipient
17	
18	This PDF file includes:
19	Main Text, words 7454
20	Figures 1 to 6
21	Tables 1 and 2
22	
23	

1 Main Text

2 Abstract

3 A small percentage of bladder cancers in the general population have been found to harbor 4 DNA viruses. In contrast, up to 25% of tumors of solid organ transplant recipients, who are at an 5 increased risk of developing bladder cancer and have overall poorer outcome, harbor BK 6 polyomavirus (BKPvV). To better understand the biology of the tumors and the mechanisms of 7 carcinogenesis from potential oncoviruses, we performed whole genome and transcriptome 8 sequencing on bladder cancer specimens from 43 transplant patients. Nearly half of tumors 9 from this patient population contained viral sequences. The most common were from BKPyV 10 (N=9, 21%), JC polyomavirus (N=7, 16%), carcinogenic human papillomaviruses (N=3, 7%), 11 and torque teno viruses (N=5, 12%). Immunohistochemistry revealed variable Large T antigen 12 expression in BKPyV-positive tumors ranging from 100% positive staining of tumor tissue to less 13 than 1%. In most cases of BKPyV-positive tumors, the viral genome appeared to be clonally 14 integrated into the host chromosome consistent with microhomology-mediated end joining and 15 coincided with focal amplifications of the tumor genome similar to other virus-mediated cancers. 16 Significant changes in host gene expression consistent with the functions of BKPvV Large T 17 antigen were also observed in these tumors. Lastly, we identified four mutation signatures in our 18 cases with those attributable to APOBEC3 and SBS5 being the most abundant. Mutation 19 signatures associated with the antiviral drug, ganciclovir, and aristolochic acid, a nephrotoxic 20 compound found in some herbal medicines, were also observed. The results suggest multiple 21 pathways to carcinogenesis in solid organ transplant recipients with a large fraction being virus-22 associated.

23

24 Author Summary

Solid organ transplant recipients are at a significantly increases risk for developing bladder
 cancer compared to the general population, suggesting a potential infectious origin to these

1 tumors. This study identifies that BK polyomavirus, JC polyomavirus, human papillomaviruses, 2 and anelloviruses are commonly found in bladder tumors of solid organ transplant recipients. In 3 most cases when detected, BK polyomavirus is integrated into the tumor genome and 4 associates with genomic structural changes and distinct gene expression through the activity of 5 viral oncogenes. Additionally, mutational signature analysis suggests that a subset of tumors of 6 solid organ transplant recipients develop through distinct mutagenic processes compared to the 7 general population. Together these results indicate multiple distinct mechanisms of 8 carcinogenesis in bladder cancers of solid organ transplant recipients that may have 9 implications for prevention, treatment, and outcome. 10 11 Introduction

12 At least 20% of all cancers are attributable to viral, bacterial, or parasitic infections (1). The 13 advent of high-throughput deep sequencing has provided unprecedented opportunities to learn 14 how infectious agents are involved in cancer in an unbiased manner. Several previous studies 15 have searched for microbial nucleotide sequences in The Cancer Genome Atlas (TCGA), the 16 International Cancer Genome Consortium (ICGC), and PanCancer Analysis of Whole Genomes 17 (PCAWG) datasets (2, 3). In addition to confirming known associations, such as the presence of 18 human papillomaviruses (HPVs) in cervical cancer, these studies also uncovered rare cases in 19 which viral sequences were unexpectedly found in other major cancers affecting the general 20 population (3).

21

Despite the immense amount of tumor sequencing data generated to date, the identification of microorganisms in common cancers through these studies has been limited. A more focused assessment of groups at increased risk for virus-associated cancers may be needed. In particular, oncogenic viruses may contribute to a larger fraction of cancer cases among immunosuppressed individuals, such as those with human immunodeficiency virus (HIV)

1	infection and organ transplant recipients. These populations have been previously shown to be
2	at increased risk for developing papillomavirus-mediated cancers, and the oncogenic viruses,
3	KSHV and Merkel cell polyomavirus, were discovered in these patients (4-6).
4	
5	Roughly a dozen "high-risk" HPV types cause nearly all cervical cancers, a large majority of
6	other anogenital cancers, and about half of all oropharyngeal cancers (7). The carcinogenic
7	effects of these small circular double-stranded DNA viruses are primarily dependent on
8	expression of the E6 and E7 oncogenes which, among a wide range of other functions,
9	inactivate the tumor suppressor proteins p53 and Rb, respectively (8-12).
10	
11	Polyomaviruses share many biological features with papillomaviruses. In particular,
12	polyomavirus T antigens perform many of the same functions as papillomavirus oncoproteins
13	and are similarly oncogenic in cellular and animal models (13). Merkel cell polyomavirus
14	(MCPyV) has been identified as an etiological factor in a rare skin cancer, Merkel cell carcinoma
15	(5, 14, 15). Another human polyomavirus, BK polyomavirus (BKPyV), has a long-debated
16	history as a candidate cancer-causing virus. Several case reports have described the detection
17	of BKPyV in bladder cancers arising in transplant recipients, and kidney recipients who develop
18	BKPyV viremia or BKPyV-induced nephropathy (BKVN) after transplant are at increased risk of
19	bladder cancer (16-19).
20	
21	Similar to HPV-induced cervical and oropharyngeal cancers, bladder cancers exhibit somatic
22	point mutations that are largely attributable to the activity of APOBEC3 family cytosine

23 deaminases (20-22). These enzymes normally function as innate immune defenses against

viruses by deaminating cytosines in single-stranded DNA, leading to hypermutation of the viral

- 25 genome (23). Commonly, APOBEC3 enzymes, particularly APOBEC3A and APOBEC3B, can
- 26 become dysregulated and cause carcinogenic damage to cellular DNA during the development

of various types of cancer (24). APOBEC3A and APOBEC3B are upregulated in response to
 expression of HPV E6 and E7, and APOBEC3A can restrict HPV replication (25-29). The large
 T antigens (LTAgs) of BKPyV and JC polyomavirus (JCPyV, a close relative of BKPyV) also
 upregulate APOBEC3B expression and activity (30-32).

5

6 To characterize the mutational, transcriptomic, and viral landscapes of bladder cancers arising 7 in immunosuppressed individuals, we evaluated archived tissues from 43 solid organ transplant 8 recipients who developed this malignancy. We performed total RNA sequencing and whole 9 genome sequencing (WGS) from these tissues. We utilized high-sensitivity methods and 10 comprehensive reference sequences for conserved viral proteins to identify known viral species 11 and to search for divergent viruses. Once viruses were identified, we further evaluated the 12 sequence data for integration events, point mutations, mutation signatures, and differentially 13 expressed genes to identify differences correlating with the presence of these viruses and their 14 integration state.

15

16 Results

17 Bladder cancers from transplant recipients

18 The study population was comprised of 43 U.S. bladder cancer cases from patients who 19 developed cancer after receiving solid organ transplantation (Table 1). Seventy percent were 20 male and 70% non-Hispanic white. The median age at cancer diagnosis was 65 years (range: 21 27-82). The most commonly transplanted organ was the kidney (56%), followed by heart and/or 22 lung (33%) and liver (9%). Primary tumors were roughly an equal mixture of high- and low-grade 23 carcinomas diagnosed a median of 5.7 years after transplantation. Twelve cases were 24 categorized as in situ as defined by the Surveillance, Epidemiology, and End Results (SEER) 25 Program, with two of those cases being transitional cell carcinomas in situ and ten cases being 26 noninvasive papillary transitional cell carcinomas. Invasive cases were mostly categorized into

1 the localized stage (n=20, 46%), which includes tumors that have invaded into the mucosa, 2 submucosa, muscle or subserosa. The eleven remaining cases either had regional or distant 3 invasion or metastasis. We successfully generated WGS data for 39 primary tumors, 3 4 metastases, and 3 normal tissues, with a median of 31x coverage across the human genome 5 (range: 14-55x). We generated total RNA sequencing data for 42 primary tumors, 5 metastases, 6 and 15 normal tissues, with a median of 30 million reads per sample (range: 4-65.5 million). 7 8 Detection of viruses in bladder cancers from transplant recipients 9 Analysis of WGS data for 39 primary tumors identified one or more virus species in 16 10 specimens (41%) (Figure 1A). RNA sequencing on tumor samples for which WGS data could 11 not be obtained revealed three additional cases containing viral sequences (45% of samples 12 overall). Among the 20 virus-positive primary tumors, the majority harbored BKPyV (n=9) or 13 JCPvV (n=7). High-risk HPV genotypes 16 and 51 were detected in one and two tumors. 14 respectively. A low-risk papillomavirus, HPV28, was observed in TBC33. One BKPyV-containing 15 tumor (case TBC05) also harbored relatively abundant amounts of HPV20. Only two reads 16 mapped to HPV20 in the RNA dataset for case TBC05. Sequencing of metastases confirmed 17 the presence of BKPyV in TBC06, JCPyV in TBC34, and HPV16 in TBC10. Additionally, 18 sequencing of two separate tumor sections for TBC03 and TBC09 confirmed the presence of 19 BKPyV in both. 20

WGS from TBC16, TBC17, TBC18, TBC19, TBC20, TBC21, TBC22, TBC23, TBC24, TBC27 had low numbers of reads mapping to the BKPyV genome that were judged to be attributable to low levels of index-hopping from TBC01, a papillary urothelial neoplasm of low malignant potential (PUNLMP) that had extremely high BKPyV coverage and was sequenced in the same run. Considering this, along with the absence of RNA reads supporting the presence of BKPyV, we scored these tumors virus-negative.

1

2	A separate set of searches aimed at identifying divergent members of other virus groups
3	revealed that several tumors (TBC08, TBC14, TBC25, TBC28, and TBC35) and normal tissues
4	(TBC35, TBC28, TBC39) harbored torque teno virus (TTV) sequences from either WGS or RNA
5	sequencing (Supplemental Table S3). Epstein Barr virus was most strongly detected in one
6	normal lymph node (TBC23) and, at low levels, in tumors TBC07 and TBC08. Considering the
7	stronger epidemiological evidence for BKPyV and bladder cancer and its abundance in these
8	specimens, we focused the majority of our analysis on characterizing these tumors.
9	
10	Features of BKPyV-positive tumors
11	BKPyV sequences detected in this study came from every genotype except IV (Figure 2A). One
12	patient with a BKPyV-positive tumor had a documented history of BKVN. We identified
13	unambiguous BKPyV integration sites in five of the nine BKPyV-positive tumors and in one
14	normal tissue (Figure 2B & Table 2). For three tumors a single integration junction was
15	identified, and in TBC02 three junctions were identified. In case TBC03, two separate sections
16	from separate blocks of the primary tumor were sequenced. In one of the two sections, 11
17	integration junctions were identified across seven chromosomes. Only three of the junctions
18	could be identified in the second section of the tumor, suggesting either that these junctions
19	were not present throughout the tumor or there was insufficient tumor purity/sequencing depth
20	to detect them.

21

Integration appeared consistent with a microhomology-mediated end-joining (MMEJ) model for integration, as 20 of 25 junctions (80%) had microhomology greater than or equal to 2 bp. In this model, which has previously been proposed for both HPV- and MCPyV-associated tumors (33-35), microhomologies between the virus and host genomes initiate DNA repair processes that can, in some cases, lead to tandem head-to-tail concatemeric repeats of the viral genome as

1 well as focal amplifications of the flanking host chromosome. Consistent with this model, focal 2 amplifications adjacent to BKPyV integration sites were identified in three patient tumors. In 3 TBC03, amplification of a 17 kb region of chromosome 1 flanking a multi-copy BKPyV integrant 4 was observed in two tumor sections (Figure 2C). In TBC04, a 15 kb single-copy amplification of 5 chromosome 3 was identified. Lastly, a 195 kb region of chromosome 6 was amplified next to 6 the BKPyV integration junction in TBC08. Twenty-two of the identified 25 junctions (88%) 7 intersected protein coding genes and thus might conceivably affect gene expression or function. 8 9 BKPyV RNA and DNA abundance by sequencing generally did not correspond to specimen 10 tumor purity or the percentage of LTAg+ cells (Figure 3A and B). Gene level analysis of the 11 RNA sequencing data revealed that nearly all polyomavirus-positive tumors predominantly 12 expressed the T antigens, with little to no expression of the late genes VP1 and VP2 (encoding 13 the major and minor capsid proteins, respectively) (Figure 3A and C, Supplemental Figure S1). 14 The LTAg open reading frames (ORFs) in these cases were truncated before the helicase 15 domain through deletions, frameshifts, or point mutations. An exception was the BKPyV-positive 16 PUNLMP case TBC01, which showed balanced expression of both early and late regions. 17 18 BKPyV isolates found in cases of polyomavirus nephropathy typically have rearrangements in 19 the regulatory region that enhance viral replication in cell culture. However, in this study, TBC01 20 was the only polyomavirus-positive tumor showing evidence of regulatory region 21 rearrangements (Supplemental Figure S1). 22 23 Immunohistochemistry (IHC) for polyomavirus LTAg was performed on 18 specimens suspected 24 to contain polyomaviruses and two negative control specimens determined to be free of 25 detectable viral sequences. Control sections were negative for TAg staining, whereas 11 of the 26 18 specimens that contained polyomavirus sequences showed at least some evidence for TAg

1 positivity (Figure 3B and Supplemental Figure S1). Three tumors scored as BKPyV sequence-2 positive had strong to moderate LTAg staining in greater than 80% of tumor cells, but the other 3 BKPyV-positive tumors had more variable staining. Moderate to weak staining was visible in 4 less than 0.5% cells in the primary tumor for TBC06 (Figure 3D), but strong staining was 5 observed in about 25% of cells in the metastasis. For TBC09, one sample of the tumor was 6 >90% positive for LTAg staining and another sample was less than 25% positive (Supplemental 7 Figure S1). The normal tissue for TBC09 showed BKPyV RNA and DNA coverage along a small 8 portion of the regulatory region and small T antigen, but no staining for LTAg. Although TBC01 9 had very high levels of BKPyV DNA and RNA reads, it had the lowest observed proportion of 10 LTAg-positive cells (<1% in a section that was >95% tumor). LTAg-positive cells in the TBC01 11 sample were almost entirely localized to the luminal margin of the tumor (Figure 3D).

12

Differential gene expression analysis for BKPyV-positive tumors versus virus-negative tumors revealed 1062 genes that were significantly differentially regulated in tumors harboring BKPyV (Figure 4A, Supplementary Table S4). Clustering all primary and metastatic tumors by genes with a greater than three-fold difference of expression in the above comparison, we identified three major groups that loosely correspond to the amount of BKPyV DNA and RNA in a tumor (Figure 4C). A notable exception is the BKPyV-positive tumor TBC01, which falls into the cluster mostly containing virus-negative tumors.

20

The cluster exclusively containing tumors harboring integrated BKPyV is defined by high expression of genes involved in DNA damage responses, cell cycle progression, angiogenesis, chromatin organization, mitotic spindle assembly and chromosome condensation/separation as well as some genes associated with neuronal differentiation. Overall, these tumors have relatively low expression of keratins and genes associated with cell adhesion. Genes previously shown to be associated with cell proliferation in bladder cancer, such as FGFR3, had

1	significantly lower expression in BKPyV-positive tumors relative to virus-negative tumors.
2	Notably, tumors harboring BKPyV had significantly higher average APOBEC3B expression
3	compared to both normal tissues and tumors not containing any virus (Figure 4B). This
4	observation is maintained after stratifying the cases by the germline variant, rs1014971, known
5	to associate with increased APOBEC3B expression and bladder cancer risk with highest
6	average APOBEC3B expression observed in tumors with both BKPyV and two copies of
7	rs1014971 (Supplemental Figure S2).
8	
9	In TBC03, the observed BKPyV integration into Breast Cancer Antiestrogen Resistance 3
10	(BCAR3) results in increased expression of the host gene. Further evaluation of RNA reads
11	covering this region revealed a general enrichment of sense and antisense reads mapping to
12	positions 93,688,393-93,704,476, corresponding to the amplified chromosomal region observed
13	in the WGS dataset. There is an even greater enrichment of mapped reads between positions
14	93,694,469-93,696,857. No increases in expression in nearby host genes were observed for
15	other cases and integration events.
16	
17	Aside from integration related copy number changes (CNVs), large scale CNVs overall differed
18	between BKPyV-positive and virus-negative tumors (Figure 5, Supplementary Table S6).
19	BKPyV-positive tumors showed moderate enrichments for gains of chromosome segments 1q,
20	2p, 3p, 7q, 20q and 22q, while losses of chromosome 2q, 6q, and 10q were also observed more
21	frequently in BKPyV-positive tumors versus virus-negative tumors. Similar differences in copy
22	numbers have been observed for virus-positive and virus-negative Merkel cell carcinoma (33).
23	
24	Features of other virus-positive tumors
25	In the cases that were positive for JCPyV, DNA and RNA coverage depth was much lower than
26	observed for BKPyV-positive tumors, and in several DNA-positive cases JCPyV transcription

was not detected (Figure 1). JCPyV reads were detected in three samples from case TBC12
including the primary tumor, tumor-positive lymph node, and adjacent normal bladder wall
(Supplemental Figure S3). IHC detected sparse LTAg staining in JCPyV-positive case TBC13,
but not in any tissue samples for TBC12.

For two of three cases harboring HPV types known to cause cervical cancer (HPV16 and HPV51), transcripts encoding the E6 and E7 oncogenes were detected (Supplemental Figure S4). In one HPV16+ case (TBC10), viral oncogene RNA expression was detected in both the primary and metastatic specimens. A possible HPV51 integration event in TBC32 appears to have involved a Mer4-int retrotransposon. Lastly, one case harbored DNA sequences aligning to HPV20 and a single case harbored DNA aligning to HPV28; however, no RNA reads were detected for these cutaneous HPV types (Supplemental Figure S4).

13

For the five TTV-positive tumors, the WGS analyses did not show evidence of integration. However, we were unable to assemble complete circular genomes for any of the TTVs. The missing segments all overlapped the GC-rich origin of replication that forms stable hairpins and is therefore relatively resistant to sequencing with standard Illumina technology (36). All observed TTV ORF1 sequences belonged to the *Alphatorquevirus* genus and had 51-100% amino acid identity to previously reported TTV strains (Supplemental Table S3).

20

21 Mutation signature analysis

The overall tumor mutation burden, as measured by non-synonymous mutations per million bases, did not show a clear correlation with the presence of viral sequences (Figure 6A). We analyzed likely somatic point mutations from all tumors and deconvoluted mutation signatures (Figures 6B and 6C, Supplemental Figure S5). As expected for bladder cancer, we commonly observed single-base substitution 2 (SBS2) and SBS13 (both characteristic of APOBEC3

mutagenesis, N=13 cases) and SBS5 (associated with smoking history and ERCC2 mutations,
 N=11 cases).

3

4 Four tumors (TBC16, TBC28, TBC31, TBC33) carried a predominant SBS22 signature, which is 5 caused by the chemical aristolochic acid found in the birthwort family of plants. Cases with this 6 signature showed a very high mutational burden (Figure 6A). In support of the idea that cases 7 with strong SBS22 signatures arose through environmental exposure, one such case, a kidney 8 recipient, was previously diagnosed with Chinese herbal medicine nephropathy. The final 9 deconvoluted signature closely matched the mutation spectrum caused by the deoxy-guanosine 10 analog, ganciclovir, recently identified in hematopoietic stem cell transplant recipients (Figure 11 6B) (37). 12

13 Recurrent somatic mutations

Numerous cellular genes were found to recurrently harbor nonsynonymous, nonsense, and frameshift mutations (Figure 6E). The spectrum of frequently mutated genes is similar to those reported in various types of urothelial carcinoma (e.g., mutations in *KMT2D*, *KDM6A*, and *ARID1A*) (Supplemental Table S5)(20, 38, 39). No nonsynonymous mutations were identified in *FGFR3* or *PIK3CA*, even though these genes are commonly mutated in non-muscle invasive bladder cancer (NMIBC) (40). Mutations in *TP53*, which are common in muscle-invasive bladder cancer (20), were detected in four tumors (Figure 6E).

21

22 To address the reproducibility of mutation calls in deep sequencing of FFPE samples, we

23 analyzed the sequences from two independent sections from separate blocks for three tumors

24 (Figure 6D). Comparing the variants called in these tumors, 77-82% of inferred somatic

25 mutations were common to both sections. Furthermore, a similar comparison showed a large

26 percentage of variants in common between primary tumors and their metastases (Figure 6D). In

TBC06, 84% of the likely somatic mutations in the metastasis were found in the primary tumor, whereas only 28% of the likely somatic variants in the primary tumor were found in the metastasis. In an additional primary-metastatic pair (TBC34), we identified a similar proportion of shared "trunk" mutations but the metastasis had more unique, likely somatic variants.

5

6 Discussion

7 This report presents a comprehensive molecular assessment of 43 bladder cancers arising in

8 solid organ transplant recipients by WGS and total RNA sequencing. DNA and/or RNA

9 sequences of human BK or JC polyomaviruses were detected in 16 tumors (37%). Expression

10 of the polyomavirus LTAg was documented immunohistochemically in ten cases. HPV

11 sequences were detected in six cases, including four cases with HPV types known to cause

12 cervical cancer. Overall, this is a much higher frequency of small DNA tumor virus sequence

13 detection compared to prior surveys of bladder cancers affecting the general population, where

14 fewer than 5% of tumors harbor small DNA tumor virus sequences (3, 41). The results suggest

15 that human polyomaviruses and papillomaviruses can play a carcinogenic role in the

16 development of bladder cancer, particularly among transplant recipients.

BKPyV infection in organotypic urothelial cell culture has been shown to promote cellular proliferation, consistent with the known transforming effects of its T antigens (42). Interestingly,

19 we observed frequent clonal loss of the p53-inactivating helicase domain of BKPyV LTAg due to

20 deletions and point mutations in the integrated virus. While such deletions in LTAg are

21 commonly observed in MCPyV-positive Merkel cell carcinoma (14), MCPyV LTAg lacks the p53-

22 inactivating activity of the C-terminal helicase domain of BKPyV. One might thus have expected

23 the C-terminal portion of BKPyV LTAg to be preserved in tumor cells. We speculate that the loss

24 of the BKPyV helicase domain is driven by negative selection against deleterious effects of

25 LTAg on tumor survival (e.g., LTAg might unwind the integrated BKPyV origin of replication and

26 initiate "onion skin" DNA structures leading to chromosomal instability and cell death). The

1 absence of the p53-binding domain may be compensated for in some BKPyV-positive tumors 2 through the significantly increased expression of the ubiquitin ligase TRIM71 that we observed. 3 TRIM71 has been shown to bind and poly-ubiguitinate p53 for proteasomal degradation and 4 prevent apoptosis during stem cell differentiation (43). 5 We also observed amplification of the host genome surrounding BKPyV integration sites. 6 consistent with circular DNA intermediates and/or MMEJ break-induced replication. Similar 7 findings have been reported for HPV and MCPyV-associated tumors (33, 44). These 8 amplification events result in a variable number of tandem head-to-tail copies of the virus and 9 host genome that are thought to create super-enhancers affecting viral and host gene 10 expression (45, 46). In cervical cancer, frequently only one integration event is transcriptionally 11 active; however, in tumors carrying integrated BKPyV sequences, the abundance of viral DNA 12 and RNA are positively correlated, suggesting that each integrated copy produces viral 13 transcripts. While the observed integration sites in this study are unique and have not been 14 observed in Merkel cell carcinoma, HPV16 integration has been reported previously in BCAR3 15 (47). Elevated expression of BCAR3 has been shown to increase proliferation, motility, and 16 invasiveness of estrogen receptor-positive breast cancer cells after treatment with antiestrogens 17 (48, 49).

In five tumors harboring integrated BKPyV sequences (TBC02, TBC03, TBC05, TBC06 and TBC08), we observed significant upregulation of genes associated with cell cycle progression, DNA damage, histones, and the mitotic spindle. Tumors with evidence of BKPyV integration also exhibited significant downregulation of keratins and cell adhesion genes. The latter may contribute to the high grade and invasive behavior of BKPyV-positive tumors observed in this study and others (50-54).

24 Many of the observed gene expression changes are consistent with known effects of 25 BKPyV infection and the specific activities of LTAg, which binds Rb-family proteins and alters 26 the active pool of E2F transcription factors in the cell (55, 56). Recent studies have shown that

1 APOBEC3B expression is repressed by the DREAM complex (which is composed of Rb-family 2 proteins and E2F transcription factors (30)) and, accordingly, we found that APOBEC3B is more 3 highly expressed in BKPyV-positive tumors compared to normal tissues and tumors without 4 tumor virus sequences likely due to LTAg activity. However, despite this increased expression, 5 the mutation signature commonly attributed to APOBEC3B did not appear enriched in BKPyV-6 positive tumors versus other tumors. It is possible that tumors expressing BKPvV LTAg and 7 increased APOBEC3B manifested greater intratumor heterogeneity, but we were unable to 8 detect possible low frequency APOBEC3-mediated variants from FFPE tissue without deeper 9 and more accurate sequencing. Additionally, consistent with the disruption of the DREAM 10 complex in these tumors, we observed higher expression of MYBL2, a key component of the 11 MMB complex, and one of its targets, FOXM1, which regulates numerous genes required for 12 G2/M progression. We also observed increased expression of FOXM1 downstream targets 13 associated with the centromere and kinetochore, which have been shown to promote improper 14 chromosome segregation and tumorigenesis (57-59).

15 BKPyV-positive tumors in our study had significantly higher expression of a number of 16 genes that promote homologous recombination (e.g. RAD51, RAD54L, BRCA1, and BRCA2) 17 and protect against replication fork stalling and collapse (e.g RAD51, XRCC2, and FANCB) 18 relative to virus-negative tumors (60). Claspin (CLSPN) and TIMELESS, which interact with 19 replicative polymerases and helicases are also highly expressed in BKPyV-positive tumors, 20 further promoting replication fork progression and genome stability (61). This expression pattern 21 might promote cell survival in the face of genomic damage caused by viral genome integration, 22 oncogene expression, and APOBEC3B upregulation.

While HPVs are not generally considered causative agents of bladder cancer, they have
been detected in rare cases of bladder cancer affecting immunocompetent and
immunosuppressed patients (2, 3, 62). In the current study, we identified four tumors with
carcinogenic *Alphapapillomavirus* sequences (HPV16 or HPV51). *Alphapapillomaviruses* are

1 believed to cause cancer through sustained expression of their E6 and E7 oncoproteins, which 2 is frequently associated with integration of the papillomavirus genome into the tumor genome. 3 One case in the panel carried sequences of HPV20, a *Betapapillomavirus* that can 4 cause cutaneous squamous cell carcinoma in animal model systems (63). The possible 5 involvement of *Betapapillomaviruses* in skin cancer in the general population remains 6 controversial (64). In epidermodysplasia verruciformis, a rare syndrome caused by defects in 7 zinc-binding proteins EVER1 and EVER2, patients frequently develop non-melanoma skin 8 cancers containing *Betapapillomaviruses* (65). Expression of E6 and E7 from 9 Betapapillomaviruses has been shown to promote cell survival in the face of ultraviolet radiation 10 damage and other carcinogenic insults (63, 64, 66). In the context of bladder cancer, it is 11 possible that cutaneous papillomaviruses likewise enable the accumulation of carcinogenic DNA 12 damage. Additionally, identification of HPV28, an Alphapapillomavirus that is not generally 13 associated with cervical cancer, suggests more abundant papillomavirus infections of the 14 bladder than previously assumed, with unknown implications for carcinogenesis. 15 An explanation for the observation that viruses are more prevalent in bladder cancers 16 affecting solid organ transplant recipients compared to cases in the general population is that, in 17 combination with immune suppression, transplant recipients may often become newly infected 18 through transmission from the donor graft at the time of transplantation, perhaps with a different 19 viral genotype than present in the host previously. This phenomenon is commonly observed in 20 kidney transplantation and is associated with BKVN (67), but has not been documented for 21 heart, lung, or liver transplant recipients, who are also included in the current study. The lack of 22 detection of BKPyV genotype IV in this study may indicate that this genotype represents a less 23 carcinogenic strain, reminiscent of "low risk" HPV types that are rarely found in tumors. 24 Additionally, this study and one prior study (68) identified JCPyV in bladder tumors. Based on 25 the high degree of similarity between JCPyV and BKPyV, it seems reasonable to expect that the 26 two species would behave similarly. However, the low abundance of JCPyV RNA and DNA in

these specimens and absence of integration, together with the ubiquity of latent JCPyV
 infections in the urinary tract, raises the possibility that these observations reflect incidental
 detection events.

4 The data from this study and others suggest that in the context of strong immune 5 suppression BKPyV can cause bladder cancer through clonal integration but is rarely detected 6 in tumors of the general population. While most adults are seropositive for BKPyV with at least 7 10% having detectable BKPyV in the urine, BKPyV is only observed in upwards of 4% of 8 NMIBC cases and less than 0.25% in muscle-invasive bladder cancers in the general population 9 (3, 41). This implies that, while BKPyV LTAg can provide a growth advantage to cells in culture, 10 the large multi-domain antigen may be relatively immunogenic compared to the much smaller 11 oncoproteins encoded by high-risk HPVs or the highly truncated MCPyV LTAg isoforms typically 12 observed in tumors. Immunologic recognition of these tumors may also be impacted by the 13 increased expression of APOBEC3B, which can generate immunogenic neoantigens (69, 70). 14 Several reports of regression of patients' BKPyV-positive tumors after reduction of immune 15 suppression support the idea that tumors constitutively expressing BKPyV gene products are 16 readily targeted and controlled by the immune system (71-73). The theoretical immunological 17 costs of viral gene expression for a nascent tumor cell raise the possibility of "hit-and-run" 18 carcinogenesis. The hit-and-run hypothesis invokes the idea that a virus may play a causal role 19 in early stages of carcinogenesis but then become undetectable at more advanced stages of 20 tumor development. Infection of a premalignant cell may promote its growth and survival 21 through the expression of the viral oncogenes. Additionally, expression of viral oncogenes may 22 also promote genome instability through the expression of the mutagenic APOBEC3 enzymes 23 or other mechanisms that further push the cell towards transformation as has been suggested 24 by a recent study of BKPyV infection in differentiated urothelium (74).

The heterogeneous expression of LTAg observed in this study could represent
 transcriptional silencing or loss of BKPyV DNA from one part of the tumor, supporting the idea

1 that tumors can lose the need for LTAg expression. Alternatively, our observations could be 2 accounted for by a multistage integration and carcinogenesis process proposed by other recent 3 studies on BKPyV-positive urinary tumors from kidney transplant recipients (75, 76). However, 4 our sequencing experiments support a dominant clonally integrated form likely established early 5 during tumor development in most BKPyV-positive tumors in this study. The only exception to 6 this observation is TBC01, which appears to exhibit a viable BKPvV episome with a rearranged 7 regulatory region present in a small subset of tumor cells. This also suggests that archetypal 8 BKPvV, rather than the more pathogenic rearranged strains found in cases of nephropathy, is 9 more likely to integrate and be preserved into nascent tumor cells. In support of the idea that 10 integration may be a common aspect of BKPyV infection, we identified a clonal BKPyV integrant 11 in the normal bladder specimen from case TBC09 in both the RNA and WGS sequencing that 12 was distinct from the BKPyV integrant observed in the tumor sample. The normal tissue 13 integrant had multiple copies of small T antigen and a large deletion in the regulatory regions 14 (Supplemental Figure S1). Only a few reads from RNA sequencing mapped to the small T 15 antigen region, and histology of the section indicates no tumor cells or LTAg staining, 16 suggesting that the virus did not integrate in the right genomic location or maintain the needed 17 components to drive carcinogenesis.

18 It remains to be seen whether TTVs contribute to disease in the context of immune 19 suppression. A general model is that these ubiquitous viruses establish a chronic infection that 20 the immune system generally keeps in check, but immune suppression results in increases not 21 only in the abundance but also the diversity of TTVs observed in hosts (77). Indeed, detection of 22 TTVs can serve as an indicator of the degree of overall immune suppression in transplant 23 recipients (78). Interestingly, these viruses, like papillomaviruses and polyomaviruses, also 24 appear to be depleted for APOBEC3 target motifs, consistent with the effects of an evolutionary 25 virus-host arms race (23, 32, 79).

1 Until recently, this type of molecular assessment from FFPE tissues would have been 2 nearly impossible or badly muddled by the highly damaging effects of formalin fixation and 3 oxidation of nucleic acids over time. Recent advancements in the isolation of nucleic acids, such 4 as low temperature and organic solvent-free deparaffinization, combined with efficient library 5 preparation from low-concentration highly degraded sources, yielded sufficiently high-quality 6 material for WGS variant calling and total RNA sequencing (80). To address the difficulty of 7 accurately calling somatic variants (which can be problematic even from flash frozen or fresh 8 tissues), we called variants using the consensus of three modern variant callers. The lack of 9 matched normal tissues for most cases is a limitation of this work, but our analytical approach 10 accounted for this by focusing the analysis on mutations with >10% allele frequency and those 11 with potential functional effects, and by excluding known germline variants. Our methods were 12 validated internally through the sequencing of separate regions from the same tumor and of 13 primary-metastatic pairs, which reveal similar concordance of mutations as has been reported 14 from flash frozen tissues (81). Our variant calling approach was also validated by the 15 observation that we detected four deconvoluted mutation signatures that match those expected 16 from prior surveys of bladder cancer. However, the low overall coverage of our WGS remains a 17 limitation of this study.

18 We identified four bladder cancers in kidney transplant recipients that exhibited 19 abundant mutations attributable to aristolochic acid-mediated DNA adducts. Aristolochic acid is 20 a highly nephrotoxic and mutagenic compound produced by birthwort plants, which sometimes 21 contaminate certain types of herbal medicines and grains (82). Exposure to this compound likely 22 contributed to the patients' need for kidney transplantation, as well as their eventual 23 development of bladder cancer. Highlighting the highly mutagenic nature of this compound, the 24 four cases with dominant aristolochic acid signature were in the top seven for total mutation 25 burden (Figure 6). None of the three tumors had detectable oncogenic viral sequences, but one 26 had detectable TTV. We also identified likely ganciclovir-mediated mutations (37) in most

1 patients indicating that this common treatment to prevent reactivation of cytomegalovirus in solid 2 organ transplant recipients may promote mutagenesis in the urinary bladder. Unfortunately, 3 ganciclovir treatment history was unavailable for these cases to confirm that this is the origin of 4 this mutation signature in these cases. Ever-decreasing sequencing costs will facilitate 5 additional studies of this type and shed light on rare and understudied tumor types, as well as 6 analyses of lower-grade and pre-cancerous lesions. 7 8 **Materials and Methods** 9 Sample acquisition and ethics 10 The Transplant Cancer Match (TCM) Study is a linkage of the US national solid organ transplant 11 registry with multiple central cancer registries (https://transplantmatch.cancer.gov/). We used 12 data from this linkage to identify cases of in situ or invasive bladder cancer diagnosed among 13 transplant recipients. Staff at five participating cancer registries (California, Connecticut, Hawaii, 14 lowa, Kentucky) worked with hospitals in their catchment areas to retrieve archived pathology 15 materials for selected cases. 16 17 We obtained twenty 10-micron sections from formal-fixed paraffin-embedded (FFPE) blocks for 18 cases with available material. At each originating institution, the microtome blade was cleaned 19 with nuclease-free water and ethanol between samples. Single 5-micron sections leading and 20 trailing the twenty sections used for nucleic acid isolation were saved for histochemistry. 21 22 The TCM Study is considered non-human subjects research at the National Institutes of Health 23 because researchers do not receive identifying information on patients, and the present project 24 utilizes materials collected previously for clinical purposes. The TCM Study was reviewed, as 25 required, by human subjects committees at participating cancer registries.

26

1 Nucleic acid isolation

Samples were simultaneously deparaffinized and digested using 400 µL molecular-grade
mineral oil (Millipore-Sigma) and 255 µL Buffer ATL (Qiagen) supplemented with 45 µL of
proteinase K (Qiagen). Samples were incubated overnight at 65°C in a shaking heat block.
Samples were spun at 16,000 x g in a tabletop microcentrifuge for one minute to separate the
organic and aqueous phases. Depending on the presence of visible remaining tissue, some
samples were subjected to one or two additional two-hour long digests by the addition of 25 µL
of fresh proteinase K buffer. Lysates were stored at 4°C until RNA or DNA isolation.

9

10 Lysates were spun at 16,000 x g in a tabletop microcentrifuge for one minute. For DNA 11 isolation, 150 µL of supernatant was moved to a new 1.5 mL tube. 490 µL of binding buffer PM 12 (Qiagen) and 10 µL of 3M sodium acetate were added to the lysate. The mixture was then 13 added to a Qiaquick spin column and spun at 16,000 x g for 30 seconds. Flow-through was 14 reapplied to the spin column for complete binding. The column was washed first with 750 µL of 15 Buffer PE (Qiagen) and then 750 µL of 80% ethanol, spinning at 16,000 x g for 30 seconds and 16 discarding flow-through each time. The column was dried by spinning it at 16,000 x g for 5 17 minutes. Collection tubes were discarded, and the column was moved to a new microcentrifuge 18 tube. 50 µL of pre-warmed, 65°C 10% buffer EB was applied to the column and incubated for 1 19 minute. The tube was then spun at 16,000 x g for 2 minutes. DNA quantity and quality were 20 assessed by Qubit (Thermo Fisher) and spectrophotometry (DeNovix). DNA was stored at -21 20°C until used for library preparation. Only samples with greater than 50ng of DNA were 22 processed for library prep.

23

For RNA isolation, 150 µL of the remaining clarified lysate was moved to a new tube. 250 µL of
buffer PKD (Qiagen) was added and vortexed to mix. The remainder of the RNA extraction
process was carried out using a RNeasy FFPE Kit (Qiagen) according to the manufacturer's

protocol. RNA quantity and quality were assessed by spectrophotometry (DeNovix) and
 TapeStation (Agilent).

3

4 *Immunohistochemistry*

5 FFPE 5-µm thick tissue sections mounted on charged glass slides were stained with antibody 6 against Large T Antigen, clone PAb416 (Sigma Millipore, cat. DP02) which detects LTAg from 7 multiple polyomaviruses. Slides were baked in a laboratory oven at 60 C for 1 hour prior to 8 immunostaining on Ventana Discovery Ultra automated IHC stainer upon following conditions: 9 CC2 (pH9) antigen retrieval for 64 min at 96 C, antibody at concentration 0.5 µg/ml in Agilent 10 antibody diluent (cat. S3022) for 32 min at 36 C, Anti-Mouse HQ-Anti HQ HRP detection 11 system for 12 min with DAB for 4 minutes and Hematoxylin II counterstain for 8 minutes. After 12 washing per manufacturer's instructions, slides were incubated in tap water for 10 min, 13 dehydrated in ethanol, cleared in xylene, coverslipped with Micromount media (Leica 14 Biosystems) and scanned on AT2 slide scanner (Leica Biosystems) for pathology review. FFPE 15 sections of cell pellets transfected with LTAg and commercial slides of SV40 infected tissue 16 (Sigma, cat. 351S) were used as positive controls.

17

18 Library preparation and sequencing

19 50-250 ng of isolated DNA was fragmented in microtube-50 using a Covaris sonicator with the 20 following settings: peak power: 100, duty factor: 30, cycles/burst: 1000, time: 108 seconds. End-21 repair and A-tailing were performed on fragmented DNA using the KAPA HyperPrep Kit 22 (Roche). NEB/Illumina adaptors were ligated onto fragments with KAPA T4 DNA Ligase for 2 23 hours at 20°C then treated with 4 µL USER enzyme (NEB) for 15 minutes at 37°C to digest 24 uracil-containing fragments. Ligation reactions were cleaned up using 0.8x AMPure XP beads 25 using the KAPA protocol. NEB dual-index oligos were added to the adaptor-ligated fragments 26 and amplified for 6-8 cycles (depending on the amount of input fragmented DNA) using KAPA

HiFi HotStart ReadyMix (Roche). Final amplified libraries were cleaned using 1x AMPure beads
with the recommended KAPA protocol. Ribosomal sequence-depleted cDNA libraries were
prepared using 50 ng of total RNA with the SMARTer Stranded Total RNA-Seq Kit v2 – Pico
Input Mammalian (Takara) following the manufacturer instructions for FFPE tissues. Final RNA
and DNA libraries were assessed for size and quantity by Agilent TapeStation. Only samples
that yielded libraries greater than 5 nM were sequenced.

7

8 DNA libraries were sequenced on the Illumina NovaSeq 6000 at the Center for Cancer

9 Research (CCR) Sequencing Facility. RNA libraries were sequenced on the Illumina NovaSeq

10 6000 and NextSeq 550 in high output mode at the CCR Genomics Core. Sequencing metrics

11 are reported in Supplemental Table S1.

12

13 Sequence alignments

Reads were trimmed using Trim Galore 0.6.0 with default settings. RNA reads were initially 14 15 aligned using STAR aligner 2.5.3ab (83) against a fusion reference human genome containing 16 hg38, all human viruses represented in RefSeq as of December 2018 (Supplemental Table S2), 17 and all papillomavirus genomes from PaVE https://pave.niaid.nih.gov (84). Default parameters 18 were used with the following exceptions: chimSegmentMin=50, outFilterMultimapNmax=1200, 19 outFilterMismatchNmax=30, outFilterMismatchNoverLmax=1. Any reads that had less than 30 20 bp of perfect identity were excluded. Trimmed DNA reads were aligned with Bowtie2 (2.3.4.3) 21 using the --very-sensitive setting to the same reference genome as mentioned above excluding 22 RNA viruses (85). Alignments were sorted and duplicate sequences were flagged using Picard 23 2.20.5. Indel realignments and base quality recalculations were conducted using GATK.

24

25 Virus detection and integration analysis

1 All WGS reads not mapping to the human genome were *de novo* assembled using MEGAHIT 2 (1.1.4) with default parameters (86). All trimmed RNA reads were assembled using 3 RNASPAdes (87). Assembled contigs were annotated using BLASTn and BLASTx against the 4 NCBI nt database (October 2021) for closely related species, and CenoteTaker2 5 (https://github.com/mtisza1/Cenote-Taker2) was used to identify more divergent species in 6 contigs \geq 1000bp (88). Depth and breadth of coverage of viral species were normalized by total 7 number of human reads and length of the viral genome. Only species with ≥10% genome 8 coverage and a normalized depth ≥10 for a viral genome in a given sample were considered as 9 hits. Viral read k-mers were cross-compared against samples for uniqueness to identify index 10 hopping or potential contamination between samples. Rearrangements in the BKPyV regulatory 11 region were analyzed and annotated using BKTyper (89).

12

13 Bam alignments were input into Oncovirus Tools (github.com/gstarrett/oncovirus tools) to call 14 integration sites (33, 90). It starts by extracting discordant read pairs (where one read aligns to a 15 sequence of interest, i.e. virus, and the mated read aligns to the human genome) and any 16 remaining reads aligned to the human genome that contain at least one 25bp k-mer from the 17 input sequences of interest as determined by a Bloom filter. It uses the human genomic 18 coordinates from the above reads to identify putative integration regions by merging their 19 stranded mapping positions to find overlaps, counting the number of reads per stranded region. 20 Oncovirus Tools then assembles the extracted reads, together with all unaligned reads, using 21 Spades (91). The resulting assembly graphs are annotated with the human and viral genomes 22 using BLASTn and the annotated assembly graphs are plotted using the R package ggraph. 23 The output is then screened for contigs containing both human and viral hits with BLASTn e-24 values below 1e-10. Based on these hits, integration junctions are called and overlaps in host-25 virus hits on the contigs are then screened for microhomology. All putative integration sites from 26 Oncovirus Tools were manually validated by returning to the original alignment file.

1

2 Transcriptome clustering and differential gene expression analysis

3 Counts from STAR were input into R and normalized using the DESeg2 vst function (92). The 4 DESeq2 model was built using the following factor: tissue type (normal, primary, metastasis), 5 grade, stage, and virus status to evaluate their effects on gene expression. Since the RNA seg 6 libraries were prepared in different batches on different days and in different sequencing runs. 7 batch effects were removed using the R package limma and the function RemoveBatchEffects. 8 These normalized counts were input into the R package ConsensusClusterPlus. Pathway 9 analysis was conducted using Enrichr (https://amp.pharm.mssm.edu/Enrichr) (93, 94). 10 11 Somatic point mutation, structural variant, and copy number variant calling 12 Point mutations were called using Mutect2, VarScan2 and lofreq with default parameters (95, 13 96). Consensus calls between these variant callers were performed using SomaticSeg (3.3.0) 14 (97). Likely germline variants were annotated and removed using SnpSift and dbSNP v152. 15 Likely somatic point mutations were further filtered by the following criteria: SomatigSeg PASS 16 filter, $\geq 10\%$ allele frequency, ≥ 4 reads supporting the variant allele, and ≥ 8 reads of total 17 coverage of that position. Common mutations in cancer were annotated using SnpSift and 18 COSMIC. Copy number variants in tumor WGS datasets were called using GATK4 CNV to 19 compare them to a panel comprised of the normal-tissue WGS datasets generated in this study. 20 Recurrent copy number variants within polyomavirus-containing tumors or tumors with no virus 21 were determined using GISTIC2 with default parameters. Visualization and variant calling for 22 BKPyV was performed on alignments against a BKPyV genotype Ib-2 isolate (accession 23 number: AB369087.1).

24

25 Mutation signature analysis

- 1 Mutation signature analysis was conducted using the likely somatic variants passing all the
- 2 above criteria. Mutational Patterns and Somatic Signatures R packages were used for de novo
- 3 somatic mutations signature analysis.
- 4
- 5 Data visualization
- 6 All graphs were made in the R statistical environment (4.0.3) using the package ggplot2 or using
- 7 Graphpad Prism.
- 8
- 9 Availability of data and materials
- 10 All refseqs for human papillomaviruses were downloaded from PaVE and refseqs for human
- 11 polyomaviruses were downloaded from NCBI as of November 2018. All data generated in this
- 12 study will be available from dbGaP under accession ######. Viral contigs from this study will be
- 13 deposited in GenBank under accessions #######. Code used in this manuscript are available
- 14 from <u>www.github.com/gstarrett</u>.
- 15
- 16

17 Funding

- 18 This work was funded by the NIH Intramural Research Program.
- 19

20 Acknowledgments

- 21 We would like to thank the CCR Genomics Core and CCR Sequencing Facility for their
- 22 assistance with sequencing. This work utilized the computational resources of the NIH HPC
- 23 Biowulf cluster (<u>http://hpc.nih.gov</u>). We would also like to thank the members of the Laboratory
- 24 of Cellular Oncology for their useful discussion and insights.
- 25 We would like to the staff at the Scientific Registry of Transplant Recipients and participating
- 26 cancer registries who assisted with collection of the data and registry linkages.

1 Disclaimer: The views expressed in this article are those of the authors and should not be

2 interpreted to reflect the views or policies of the National Cancer Institute, the Health Resources

3 and Services Administration, the Scientific Registry of Transplant Recipients, the cancer

4 registries, or their contractors.

5

6 References

de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer
 attributable to infections in 2018: a worldwide incidence analysis. The Lancet Global Health.
 2020;8(2):e180-e90.

10 2. Zapatka M, Borozan I, Brewer DS, Iskar M, Grundhoff A, Alawi M, et al. The landscape of 11 viral associations in human cancers. Nat Genet. 2020;52(3):320-30.

12 3. Cantalupo PG, Katz JP, Pipas JM. Viral sequences in human cancer. Virology.

13 2018;513:208-16.

Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of
 herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (New York, NY).
 1994;266(5192):1865-9.

Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human
Merkel cell carcinoma. Science (New York, NY). 2008;319(5866):1096-100.

19 6. D'Arcy ME, Castenson D, Lynch CF, Kahn AR, Morton LM, Shiels MS, et al. Risk of rare 20 cancers among solid organ transplant recipients. J Natl Cancer Inst. 2020.

7. Graham SV. The human papillomavirus replication cycle, and its links to cancer
 progression: a comprehensive review. Clin Sci (Lond). 2017;131(17):2201-21.

8. Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M, et al. Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in

invasive cervical carcinoma. Oncogene. 2005;24(47):7094-104.

26 9. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences
27 distinct from those required. Cell. 1991;67:547-56.

Mirabello L, Yeager M, Yu K, Clifford GM, Xiao Y, Zhu B, et al. HPV16 E7 Genetic
Conservation Is Critical to Carcinogenesis. Cell. 2017;170(6):1164-74.e6.

30 11. Decaprio Ja. Human papillomavirus type 16 E7 perturbs DREAM to promote cellular
 31 proliferation and mitotic gene expression. Oncogene. 2013;33(September):1-3.

32 12. Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH. The region of the

33 HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate

domains for Rb binding and casein kinase || phosphorylation. The EMBO journal. 1990;9(1):15360.

36 13. Moens U, Macdonald A. Effect of the Large and Small T-Antigens of Human

Polyomaviruses on Signaling Pathways. Int J Mol Sci. 2019;20(16).

38 14. Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, et al. T antigen mutations

39 are a human tumor-specific signature for Merkel cell polyomavirus. Proceedings of the National

40 Academy of Sciences of the United States of America. 2008;105:16272-7.

Kassem A, Schöpflin A, Diaz C, Weyers W, Stickeler E, Werner M, et al. Frequent 1 15. 2 detection of merkel cell polyomavirus in human merkel cell carcinomas and identification of a 3 unique deletion in the VP1 gene. Cancer Research. 2008;68(13):5009-13. 4 16. Gupta G, Kuppachi S, Kalil RS, Buck CB, Lynch CF, Engels EA. Treatment for presumed BK 5 polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States. Am J Transplant. 2018;18(1):245-52. 6 7 Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ 17. 8 transplantation. Int J Cancer. 2009;125(8):1747-54. 9 18. Li YJ, Wu HH, Chen CH, Wang HH, Chiang YJ, Hsu HH, et al. High Incidence and Early 10 Onset of Urinary Tract Cancers in Patients with BK Polyomavirus Associated Nephropathy. Viruses. 2021;13(3). 11 12 19. Papadimitriou JC, Randhawa P, Rinaldo CH, Drachenberg CB, Alexiev B, Hirsch HH. BK 13 Polyomavirus Infection and Renourinary Tumorigenesis. Am J Transplant. 2016;16(2):398-406. 14 20. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. 15 Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 16 2017;171(3):540-56 e25. 17 21. Burns MB, Temiz Na, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human 18 cancers. Nature genetics. 2013;45(9):977-83. Roberts Sa, Lawrence MS, Klimczak LJ, Grimm Sa, Fargo D, Stojanov P, et al. An APOBEC 19 22. 20 cytidine deaminase mutagenesis pattern is widespread in human cancers. Nature genetics. 21 2013;45(9):970-6. 22 Poulain F, Lejeune N, Willemart K, Gillet NA. Footprint of the host restriction factors 23. 23 APOBEC3 on the genome of human viruses. PLoS Pathog. 2020;16(8):e1008718. 24 24. Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC enzymes: Mutagenic fuel for 25 cancer evolution and heterogeneity. Cancer Discovery. 2015;5(7):704-12. 26 Mori S, Takeuchi T, Ishii Y, Yugawa T, Kiyono T, Nishina H, et al. Human papillomavirus 25. 27 16 E6 up-regulates APOBEC3B via the TEAD transcription factor. Journal of Virology. 28 2017:JVI.02413-16. 29 Warren CJ, Westrich JA, Doorslaer KV, Pyeon D. Roles of APOBEC3A and APOBEC3B in 26. 30 Human Papillomavirus Infection and Disease Progression. Viruses. 2017;9(8). 31 Ahasan MM, Wakae K, Wang Z, Kitamura K, Liu G, Koura M, et al. APOBEC3A and 3C 27. 32 decrease human papillomavirus 16 pseudovirion infectivity. Biochemical and biophysical 33 research communications. 2015;457(3):295-9. 34 Warren CJ, Xu T, Guo K, Griffin LM, Westrich Ja, Lee D, et al. APOBEC3A functions as a 28. 35 restriction factor of human papillomavirus. Journal of virology. 2014;89(1):688-702. 36 29. Vieira VC, Leonard B, White EA, Starrett GJ, Temiz Na, Lorenz LD, et al. Human 37 papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase 38 APOBEC3B. mBio. 2014;5(6):1-8. 39 Starrett GJ, Serebrenik AA, Roelofs PA, McCann JL, Verhalen B, Jarvis MC, et al. 30. 40 Polyomavirus T Antigen Induces APOBEC3B Expression Using an LXCXE-Dependent and TP53-Independent Mechanism. MBio. 2019;10(1). 41 42 Peretti A, Geoghegan EM, Pastrana DV, Smola S, Feld P, Sauter M, et al. Characterization 31. 43 of BK Polyomaviruses from Kidney Transplant Recipients Suggests a Role for APOBEC3 in Driving 44 In-Host Virus Evolution. Cell Host Microbe. 2018;23(5):628-35 e7.

Verhalen B, Starrett GJ, Harris RS, Jiang M. Functional Upregulation of the DNA Cytosine 1 32. 2 Deaminase APOBEC3B by Polyomaviruses. Journal of virology. 2016;90(14):6379-86. 3 33. Starrett GJ, Thakuria M, Chen T, Marcelus C, Cheng J, Nomburg J, et al. Clinical and 4 molecular characterization of virus-positive and virus-negative Merkel cell carcinoma. Genome 5 Med. 2020;12(1):30. Starrett GJ, Marcelus C, Cantalupo PG, Katz JP, Cheng J, Akagi K, et al. Merkel Cell 6 34. 7 Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-8 Associated Merkel Cell Carcinoma. MBio. 2017;8(1). 9 35. Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, et al. Genome-wide analysis of 10 HPV integration in human cancers reveals recurrent, focal genomic instability. Genome research. 2014;24(2):185-99. 11 12 Tisza MJ, Pastrana DV, Welch NL, Stewart B, Peretti A, Starrett GJ, et al. Discovery of 36. 13 several thousand highly diverse circular DNA viruses. Elife. 2020;9. 14 37. de Kanter JK, Peci F, Bertrums E, Rosendahl Huber A, van Leeuwen A, van Roosmalen 15 MJ, et al. Antiviral treatment causes a unique mutational signature in cancers of transplantation 16 recipients. Cell Stem Cell. 2021;28(10):1726-39 e6. 17 Nassar AH, Umeton R, Kim J, Lundgren K, Harshman LC, Van Allen EM, et al. Mutational 38. 18 analysis of 472 urothelial carcinoma across grades and anatomic sites. Clin Cancer Res. 2018. 19 39. Su X, Lu X, Bazai SK, Comperat E, Mouawad R, Yao H, et al. Comprehensive integrative 20 profiling of upper tract urothelial carcinomas. Genome Biol. 2021;22(1):7. 21 Cancer T, Atlas G, Weinstein JN, Akbani R, Broom BM, Wang W, et al. Comprehensive 40. 22 molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-22. 23 41. Llewellyn MA, Gordon NS, Abbotts B, James ND, Zeegers MP, Cheng KK, et al. Defining 24 the frequency of human papillomavirus and polyomavirus infection in urothelial bladder 25 tumours. Sci Rep. 2018;8(1):11290. 26 Schneidewind L, Neumann T, Plis A, Bruckmann S, Keiser M, Kruger W, et al. Novel 3D 42. 27 organotypic urothelial cell culture model for identification of new therapeutic approaches in 28 urological infections. J Clin Virol. 2020;124:104283. 29 Nguyen DTT, Richter D, Michel G, Mitschka S, Kolanus W, Cuevas E, et al. The ubiquitin 43. 30 ligase LIN41/TRIM71 targets p53 to antagonize cell death and differentiation pathways during 31 stem cell differentiation. Cell Death Differ. 2017;24(6):1063-78. 32 44. Czech-Sioli M, Gunther T, Therre M, Spohn M, Indenbirken D, Theiss J, et al. High-33 resolution analysis of Merkel Cell Polyomavirus in Merkel Cell Carcinoma reveals distinct 34 integration patterns and suggests NHEJ and MMBIR as underlying mechanisms. PLoS Pathog. 35 2020;16(8):e1008562. 36 45. Warburton A, Redmond CJ, Dooley KE, Fu H, Gillison ML, Akagi K, et al. HPV integration 37 hijacks and multimerizes a cellular enhancer to generate a viral-cellular super-enhancer that 38 drives high viral oncogene expression. PLoS Genet. 2018;14(1):e1007179. 39 Dooley KE, Warburton A, McBride AA. Tandemly Integrated HPV16 Can Form a Brd4-46. 40 Dependent Super- Enhancer-Like Element That Drives Transcription of Viral Oncogenes. 41 2016;7(5):2-11.

- 42 47. Jeannot E, Harle A, Holmes A, Sastre-Garau X. Nuclear factor | X is a recurrent target for
- 43 HPV16 insertions in anal carcinomas. Genes Chromosomes Cancer. 2018;57(12):638-44.

1 48. Wallez Y, Riedl SJ, Pasquale EB. Association of the breast cancer antiestrogen resistance

protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistance. J
 Biol Chem. 2014;289(15):10431-44.

4 49. Wilson AL, Schrecengost RS, Guerrero MS, Thomas KS, Bouton AH. Breast cancer 5 antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and

6 adhesion remodeling in invasive breast cancer cells. PLoS One. 2013;8(6):e65678.

Alexiev BA, Randhawa P, Vazquez Martul E, Zeng G, Luo C, Ramos E, et al. BK virusassociated urinary bladder carcinoma in transplant recipients: report of 2 cases, review of the
literature, and proposed pathogenetic model. Hum Pathol. 2013;44(5):908-17.

10 51. Sirohi D, Vaske C, Sanborn Z, Smith SC, Don MD, Lindsey KG, et al. Polyoma virus-

associated carcinomas of the urologic tract: a clinicopathologic and molecular study. ModPathol. 2018.

13 52. Kenan DJ, Mieczkowski PA, Burger-Calderon R, Singh HK, Nickeleit V. The oncogenic

potential of BK-polyomavirus is linked to viral integration into the human genome. J Pathol.
 2015;237(3):379-89.

16 53. Kenan DJ, Mieczkowski PA, Latulippe E, Cote I, Singh HK, Nickeleit V. BK Polyomavirus

Genomic Integration and Large T Antigen Expression: Evolving Paradigms in Human
 Oncogenesis. Am J Transplant. 2017;17(6):1674-80.

19 54. Nickeleit V, Singh HK, Kenan DJ, Mieczkowski PA. The two-faced nature of BK

20 polyomavirus: lytic infection or non-lytic large-T-positive carcinoma. J Pathol. 2018.

21 55. Caller LG, Davies CTR, Antrobus R, Lehner PJ, Weekes MP, Crump CM. Temporal

Proteomic Analysis of BK Polyomavirus Infection Reveals Virus-Induced G2 Arrest and Highly
 Effective Evasion of Innate Immune Sensing, J Virol. 2019;93(16).

56. Harris KF, Christensen JB, Imperiale MJ. BK virus large T antigen: interactions with the
retinoblastoma family of tumor suppressor proteins and effects on cellular growth control.
Journal of virology. 1996;70(4):2378-86.

27 57. Fischer M, Muller GA. Cell cycle transcription control: DREAM/MuvB and RB-E2F 28 complexes. Crit Rev Biochem Mol Biol. 2017;52(6):638-62.

2958.Sadasivam S, Duan S, DeCaprio JA. The MuvB complex sequentially recruits B-Myb and30FoxM1 to promote mitotic gene expression. Genes Dev. 2012;26(5):474-89.

31 59. Schade AE, Oser MG, Nicholson HE, DeCaprio JA. Cyclin D-CDK4 relieves cooperative

32 repression of proliferation and cell cycle gene expression by DREAM and RB. Oncogene.

33 2019;38(25):4962-76.

3460.Tye S, Ronson GE, Morris JR. A fork in the road: Where homologous recombination and35stalled replication fork protection part ways. Semin Cell Dev Biol. 2021;113:14-26.

36 61. Bianco JN, Bergoglio V, Lin YL, Pillaire MJ, Schmitz AL, Gilhodes J, et al. Overexpression

of Claspin and Timeless protects cancer cells from replication stress in a checkpoint independent manner. Nat Commun. 2019;10(1):910.

39 62. Guma S, Maglantay R, Lau R, Wieczorek R, Melamed J, Deng FM, et al. Papillary

40 urothelial carcinoma with squamous differentiation in association with human papilloma virus:

41 case report and literature review. Am J Clin Exp Urol. 2016;4(1):12-6.

42 63. Michel A, Kopp-Schneider A, Zentgraf H, Gruber AD, de Villiers EM. E6/E7 expression of

43 human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation

44 of the skin in UV-irradiated SKH-hr1 transgenic mice. J Virol. 2006;80(22):11153-64.

Viarisio D, Muller-Decker K, Accardi R, Robitaille A, Durst M, Beer K, et al. Beta HPV38
 oncoproteins act with a hit-and-run mechanism in ultraviolet radiation-induced skin
 carcinogenesis in mice. PLoS Pathog. 2018;14(1):e1006783.
 Dell'Oste V, Azzimonti B, De Andrea M, Mondini M, Zavattaro E, Leigheb G, et al. High

- beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis. J
 Invest Dermatol. 2009;129(4):1026-34.
- 7 66. Viarisio D, Muller-Decker K, Zanna P, Kloz U, Aengeneyndt B, Accardi R, et al. Novel ss8 HPV49 transgenic mouse model of upper digestive tract cancer2016.
- 9 67. Solis M, Velay A, Porcher R, Domingo-Calap P, Soulier E, Joly M, et al. Neutralizing
- Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy. J Am Soc Nephrol.2018;29(1):326-34.
- 12 68. Querido S, Fernandes I, Weigert A, Casimiro S, Albuquerque C, Ramos S, et al. High-
- 13 grade urothelial carcinoma in a kidney transplant recipient after JC virus nephropathy: The first
- 14 evidence of JC virus as a potential oncovirus in bladder cancer. Am J Transplant.
- 15 2020;20(4):1188-91.
- 16 69. Serebrenik AA, Starrett GJ, Leenen S, Jarvis MC, Shaban NM, Salamango DJ, et al. The
- deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase. Proc Natl AcadSci U S A. 2019;116(44):22158-63.
- 19 70. Chen Z, Wen W, Bao J, Kuhs KL, Cai Q, Long J, et al. Integrative genomic analyses of
- $20 \qquad {\sf APOBEC}{-} {\sf mutational signature, expression and germline deletion of APOBEC3 genes, and}$
- immunogenicity in multiple cancer types. BMC Med Genomics. 2019;12(1):131.
- 22 71. Meier RPH, Muller YD, Dietrich PY, Tille JC, Nikolaev S, Sartori A, et al. Immunologic
- Clearance of a BK Virus-associated Metastatic Renal Allograft Carcinoma. Transplantation.
 2021:105(2):423-9
- 24 2021;105(2):423-9.
- 25 72. Cuenca AG, Rosales I, Lee RJ, Wu CL, Colvin R, Feldman AS, et al. Resolution of a High
- 26 Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical
- Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report. TransplantProc. 2020.
- 29 73. Fu F, Deng W, Yu S, Liu Y, Yu L, Liu R, et al. Occurrence and regression of BK
- 30 polyomavirus associated carcinoma: a clinical and next-generation sequencing study. Clin Sci
- 31 (Lond). 2018;132(16):1753-63.
- 32 74. Baker SC, Mason AS, Slip RG, Skinner KT, Macdonald A, Masood O, et al. Induction of
- APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKPyV) as a
 hit-and-run driver for bladder cancer. Oncogene. 2022;41(15):2139-51.
- 35 75. Jin Y, Zhou Y, Deng W, Wang Y, Lee RJ, Liu Y, et al. Genome-wide profiling of BK
- polyomavirus integration in bladder cancer of kidney transplant recipients reveals mechanisms
 of the integration at the nucleotide level. Oncogene. 2021;40(1):46-54.
- 38 76. Wang Y, Liu Y, Deng W, Fu F, Yan S, Yang H, et al. Viral integration in BK polyomavirus-
- 39 associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis
- 40 revealed by next-generation virome capture sequencing. Oncogene. 2020.
- 41 77. De Vlaminck I, Khush KK, Strehl C, Kohli B, Luikart H, Neff NF, et al. Temporal response of 42 the human virome to immunosuppression and antiviral therapy. Cell. 2013;155(5):1178-87.

Blatter JA, Sweet SC, Conrad C, Danziger-Isakov LA, Faro A, Goldfarb SB, et al.

1

78.

2 Anellovirus loads are associated with outcomes in pediatric lung transplantation. Pediatr 3 Transplant. 2018;22(1). 4 Warren CJ, Van Doorslaer K, Pandey A, Espinosa JM, Pyeon D. Role of the host 79. 5 restriction factor APOBEC3 on papillomavirus evolution. Virus Evolution. 2015;1(1):vev015-vev. 6 Robbe P, Popitsch N, Knight SJL, Antoniou P, Becq J, He M, et al. Clinical whole-genome 80. 7 sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 8 100,000 Genomes Project. Genet Med. 2018;20(10):1196-205. 9 81. Zhang J, Fujimoto J, Wedge DC, Song X, Seth S, Chow CW, et al. Intratumor 10 heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014;346(6206):256-9. 11 12 Poon SL, Huang MN, Choo Y, McPherson JR, Yu W, Heng HL, et al. Mutation signatures 82. 13 implicate aristolochic acid in bladder cancer development. Genome Med. 2015;7(1):38-. 14 83. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast 15 universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21. 16 Van Doorslaer K, Li Z, Xirasagar S, Maes P, Kaminsky D, Liou D, et al. The Papillomavirus 84. 17 Episteme: a major update to the papillomavirus sequence database. Nucleic Acids Res. 18 2017;45(D1):D499-D506. 19 Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nature methods. 85. 20 2012;9(4):357-9. 21 Li D, Liu CM, Luo R, Sadakane K, Lam TW. MEGAHIT: an ultra-fast single-node solution 86. 22 for large and complex metagenomics assembly via succinct de Bruijn graph. Bioinformatics. 23 2015;31(10):1674-6. 24 Bushmanova E, Antipov D, Lapidus A, Prijbelski AD. rnaSPAdes: a de novo transcriptome 87. 25 assembler and its application to RNA-Seg data. Gigascience. 2019;8(9). 26 Tisza MJ, Belford AK, Dominguez-Huerta G, Bolduc B, Buck CB. Cenote-Taker 2 88. 27 democratizes virus discovery and sequence annotation. Virus Evol. 2021;7(1):veaa100. 28 Marti-Carreras J, Mineeva-Sangwo O, Topalis D, Snoeck R, Andrei G, Maes P. BKTyper: 89. 29 Free Online Tool for Polyoma BK Virus VP1 and NCCR Typing. Viruses. 2020;12(8). 30 90. Starrett GJ. Oncovirus tools. GitHub2020. 31 91. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a 32 new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 33 2012;19(5):455-77. 34 Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for 92. 35 RNA-seq data with DESeq2. Genome Biology. 2014;15(550):1-21. 36 93. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a 37 comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 38 2016;44(W1):W90-7. 39 Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and 94. 40 collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128. 41 Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic 95. 42 mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 43 2012;22(3):568-76. 33

96. Wilm A, Aw PP, Bertrand D, Yeo GH, Ong SH, Wong CH, et al. LoFreq: a sequence-quality
 aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high throughput sequencing datasets. Nucleic Acids Res. 2012;40(22):11189-201.

4 97. Fang LT, Afshar PT, Chhibber A, Mohiyuddin M, Fan Y, Mu JC, et al. An ensemble
5 approach to accurately detect somatic mutations using SomaticSeq. Genome Biol. 2015;16:197.
6

7

8 Figure Legends

Figure 1. Detection of viral sequences. A. Primary tumors. B. Metastatic tumors. C. Normal
tissues. Viral species are shown on the rows, and each case in the cohort (represented with a
TBC number) is a column. Circle size represents the breadth or fraction of the viral genome
covered, and color represents the average depth of coverage of the viral k-mers with all
coverages over 100 binned together. Specimens without sequencing data have a gray
background.
Figure 2. Virus diversity and integration. A. Phylogenetic tree of BKPyV LTAg sequences

17 detected in tumors (red) and reference genotypes. B. Sites of BKPvV integration into host 18 chromosomes are indicated with case numbers. Two separate sections from separate FFPE 19 blocks of the primary tumor were sequenced for case TBC03 (samples TBC03.1 and TBC03.2). 20 Two separate sections were also sequenced for case TBC09, but an integration site was only 21 detected in sample TBC09.1. Integration sites were also detected in normal tissue sample 22 TBC09N. Black and gray bars indicate cytogenetic bands; red bars indicate centromeres. C. 23 Coverage plot of focal amplifications adjacent to BKPyV integration sites in cases TBC03, 24 TBC04, and TBC08. BKPyV integration junctions are indicated by a black arrow. Colored 25 numbers in the body of the graph indicate coverage depth.

26

Figure 3. BKPyV DNA, RNA and LTAg detection in tumors. A. Barplots showing the
 abundance of BKPyV DNA and RNA reads standardized to human reads B. Barplots of

histologically estimated percent tumor purity and IHC-positivity for polyomavirus LTAg
expression. C. Representative coverage plots for BKPyV DNA (gray) and RNA (red) in BKPyVpositive tumors. Relative copy numbers are indicated by colored boxes and highlight the
borders of duplications and deletions in the viral genome. D. Selected images for LTAg IHC
highlighting positive staining for BKPyV-positive tumors with scale bars representing 500
microns.

7

8 Figure 4. Differential gene expression in BKPyV-positive tumors. A. Volcano plot of 9 differential gene expression between BKPyV-positive and virus-negative tumors. Significantly 10 differentially expressed genes (q-value < 0.05) with a fold change greater than 2 are in red. 11 genes with a fold change less than 2 are in pink. Non-significant genes are in gray. B. Variance 12 stabilized counts for APOBEC3B from DESeq grouped by normal tissues, virus-negative 13 tumors, and BKPyV-positive tumors showing significantly increased expression in BKPyV-14 positive tumors. C. Heatmap of Z-scores of significantly differentially expressed genes and 15 genes relevant to bladder cancer grouped by gene ontology. High expression is red, low 16 expression is blue. Tumors are colored by likely etiology: BKPyV-positive, red; JCPyV-positive, 17 goldenrod; HR-HPV-positive, blue; TTV-positive, green; aristolochic acid, purple; other, black. 18 Tumors with evidence of integration are in italics. 19

Figure 5. Copy number variants. Frequency plots for large copy number variants in A. BKPyVpositive and C. virus-negative tumors. Frequency of gains/amplifications are shown in red;
losses/deletions are shown in blue. Sample level copy number variant spectra for B. BKPyVpositive and D. virus-negative tumors. Complete deletions are in dark blue and high copy
amplifications are in red.

25

1 Figure 6. Somatic point mutations and mutation signature analysis. A. Tumor mutation 2 burden (TMB, non-synonymous mutations per million bases) for each tumor in this study. Bars 3 are colored by viral positivity (red, BKPyV; green, TTV; blue, HR-HPV; goldenrod, JCPyV) or 4 etiologic agent (aristolochic acid, purple). B. Barplots of the contribution each trinucleotide 5 substitution for the four deconvoluted signatures with the likely mutation process indicated. C. 6 Proportion of each deconvoluted signature that contributes to each sample with virus status 7 indicated by colored circles (red, BKPyV; green, TTV; blue, HR-HPV; goldenrod, JCPyV). D. 8 Number of unique and common trunk mutations in primary-metastatic tumor pairs and tumors 9 with multi-region sequencing. For TBC03, TBC09, and TBC28, branches 1 and 2 refer to two 10 separate areas of the same tumor. For TBC06 and TBC34, branches P and M refer to the 11 primary tumor and metastasis, respectively. E. Oncoprint for the top mutated genes in bladder 12 cancers of transplant patients. Tumors IDs are colored by likely etiology: BKPyV-positive, red; 13 JCPyV-positive, goldenrod; HR-HPV-positive, blue; TTV-positive, green; aristolochic acid, 14 purple; other, black.

1 Tables:

2 Table 1. Characteristics of post-transplant bladder cancer cases (N=43)

Characteristic	Statistic					
Sex, N (%)						
Female	13	(30)				
Male	30	(70)				
Age in years at diagnosis, median (IQR)	65	(60, 71)				
Transplanted organ, N (%)						
Kidney	24	(56)				
Liver	4	(9)				
Heart and/or lung	14	(33)				
Pancreas	1	(2)				
Race, N (%)						
Non-Hispanic White	30	(70)				
Asian/Pacific Islander	7	(16)				
Hispanic	5	(12)				
Years from transplant to diagnosis, median (IQR)	5.8	(3, 7)				
Non-Hispanic White	6.0	(4,8)				
Asian/Pacific Islander	4.7	(3,8)				
Hispanic	1.1	(1,8)				
Summary stage, N (%)						
In situ	12	(28)				
Localized	19	(46)				
Regional	7	(14)				
Distant	5	(12)				
Grade, N (%)						
Low	20	(47)				
High	22	(51)				
Papillary urothelial neoplasm of low malignant potential	1	(2)				

- 4
- 5

1 Table 2. BKPyV integrations sites and microhomology

			Maximum MH				Nearest Gene	Nearest Gene	Distance to Nearest		Distance to Nearest
ID	Human sequence match	Virus sequence match	length	MH Sequence	Chromosome	Position	(Symbol)	(Ensembl ID)	Gene	Nea rest RE	RE
TBC02	CATCATGATGATGGG	GAT G G G C A G C C T A	5	ATGGG	chr2	120378301	INHBB	ENSG 00000163083	-26499	MIRb	-45
TBC02	CTCCTGCTCATGAA	CATGAAGGTTAAGCATGCTA	5	ATGAA	chr4	145732354	C4orf51	ENSG 00000237 136	0	AluSq 2	-474
TBC02	ACCATTTAATTCCCAA	AGTGGAAATTAC	2	AC	ch r4	145732375	C4o rf 51	ENSG 00000237136	0	AluSq 2	-495
TBC03.1	GCCTTTCTTGTGGACTGGGT	ATTTTCATTTCTACTGGGGTCAGGA	0	Nooverlap	chr1	93693546	BCAR3	ENSG 00000137936	0	MIRb	377
TBC03.1	TCTGTTTCTTATTTCAGAA	GGGTTCTCCTGTTTATAAGGTC	2	тс	chr1	93693570	BCAR3	ENSG 00000137936	0	MIRb	353
TBC03.1	AGAGCCTTGGTGGTGG	GGTGGCAAACAGTGCAG	5	GGTGG	chr1	93693890	BCAR3	ENSG 00000137936	0	MIRb	33
TBC03.1	GATACTTTTTAGACATGC	AACCATGACCTCAGGAAGGA	4	CATG	chr1	93694075	BCAR3	ENSG 00000137936	0	MIRb	0
TBC03.1	CCTCAAAGCCACCCACTCC	TTTCCATGAGCCCCAAA	5	CCAAA	chr1	93694843	BCAR3	ENSG 00000137936	0	MER5 A	-92
TBC03.1	CAATTTTTTTTTT	TTTTTTTATTTGTAAGGGTG	7	тттттт	chr12	50449935	LARP4	ENSG00000161813	0	AluSc	0
TBC03.1	TGCAAGGTGCTTCATGTAT	AGGGGGCTTAAAGGATGCA	4	TGCA	chr14	95764390		ENSG 00000257 275	-6735	MIRb	0
TBC03.1	TAGCCAAAAAAAAAAAGG	AAAAAAAAGGCCACAG	11	AAAAAAAAGG	chr20	8525269	PLCB1	ENSG 0000018 2621	0	Ma mSINE1	154
TBC03.1	CAATTTGGAAAACAAT	ATGCAAGGGCAGTGCACA	2	AT	ch r3	73059264	PPP4R 2	ENSG 00000163605	0	MER103C	69
TBC03.1	TAAAAAGTGTCA	AAGTGTCAATAGAGAAAAA	8	AAGTGTCA	chr4	142307350	IN PP4B	ENSG 0000010945 2	0	L2a	0
TBC03.1	TCACACAATTT-TACTCCTCT	ACACTTTTTACACTCCTCTA	8	ACTCCTCT	ch r8	140923993	PT K2	ENSG 00000169398	0	L2a	0
TBC03.2	GTTGAGTTGGAGCA	CATCTAAATAATCTCTCAAACT	2	CA	chr1	93693160	BCAR3	ENSG00000137936	0	MER5A1	-10
TBC03.2	ACCCAGTCCACAAGAAAGGC	CCAGTAGAAATGAAAAT	0	Nooverlap	chr1	93693546	BCAR3	ENSG00000137936	0	MIRb	377
TBC03.2	TCTGTTTCTTATTTCAG	GTTCTCCTGTTTATAAGGTC	2	тс	chr1	93693570	BCAR3	ENSG 00000137936	0	MIRb	353
TBC04	GAGTGAGTTCATAG	CAACACTGTGGTGAG-TGAGTT	4	G AG T	ch r3	5202593	EDEM1	ENSG00000134109	0	L2b	-466
TBC06	CAGACATT-AGGA	TGAGGACCTAACCTGT	4	AGGA	chr2	201676427	MPP4	ENSG 0000008 2126	0	MIR1_Amn	0
TBC08	TCCACTTTCAGTACTT	тдсааааатсааат	1	т	ch r6	148535326	SAS H1	ENSG 00000111961	0	AluSq	995
TBC09.1	GGGGCGGTAACTAGAAG	ACTAGAAGCTTGTCGT	8	ACTAGAAG	chr17	61340185	BCAS3	ENSG00000141376	0	L2-3_Crp	0
TBC 09 N	GAGAAAATAGGACTCGG	AAGATTCGCCTGAGAAAA	7	GAGAAAA	chr18	8169205	PTPRM	ENSG 0000017348 2	0	ME R1 27	-648
TBC 09 N	TCCATCCTCCTCTAC	CTCCTCTACATTGT	9	CTCCTCTAC	ch r3	34028749	LINC01811	ENSG 00000226320	130585	L2b	0
TBC 09 N	ATGTAATATAAAACT	CATGATTTTAACCCAG	0	Nooverlap	ch r3	117678477		ENSG 00000239268	0	L2c	0
	2					-		-			

3

4 **Supporting Information Legends**

5

6 Figure S1. All SV40 LTAg staining, BKPyV DNA/RNA coverage, and regulatory region

7 structures. A. Coverage plots for BKPyV DNA (gray) and RNA (red) in BKPyV-positive tumors.

- 8 B. Selected images for LTAg IHC highlighting positive staining for BKPyV-positive tumors with a
- 9 scale bar representing 500 microns. C. Heatmap of normalized expression (transcripts per

1	million, TPM) of BKPyV genes per tumor. D. Diagrams of BKPyV NCCR structures and
2	rearrangements in tumors. P=Primary tumor, M=metastatic tumor.
3	
4	Figure S2. APOBEC3B germline variant and expression by BKPyV status. Stabilized
5	counts of APOBEC3B expression divided by tissue type (primary tumor, normal tissue), BKPyV
6	status (BK), and germline variant rs1014971 status.
7	
8	Figure S3. All JCPyV DNA/RNA coverage plots. Representative coverage plots for JCPyV
9	DNA (gray) and RNA (red) in JCPyV-positive tumors.
10	
11	Figure S4. All HPV DNA/RNA coverage plots. Representative coverage plots for HPV DNA
12	(gray) and RNA (red) in HPV-positive tumors. Diagrams of open reading frames for each
13	respective type are below the coverage plots.
14	
15	Figure S5. Mutations signature deconvolution. A. Residual sum of squares and explained
16	variance for 2-10 signatures deconvoluted by SomaticSignatures. B. Barplot of base
17	substitution contributions to each of the four deconvoluted signatures from SomaticSignatures.
18	C. Heatmap of cosine similarities of four signatures deconvoluted by Somatic Signatures versus
19	known Single Base Substitution Signatures (SBS). D. NMF rank survey results for 2-10
20	signature deconvolution by MutationalPatterns. E. Barplot of base substitution contributions to
21	each of the four deconvoluted signatures from MutationalPatterns. F. Heatmap of cosine
22	similarities of four signatures deconvoluted by MutationalPatterns versus known Single Base
23	Substitution Signatures (SBS) with closest matches highlighted in red.
24	
25	Table S1: Sequencing metrics

26 Table S2. Reference sequences used in this study

- 1 Table S3. Tumor torque teno virus similarities
- 2 Table S4: BKPyV-positive tumor vs virus-free tumor significantly differentially expressed genes
- 3 Table S5. Non-synonymous point mutations
- 4 Table S6. Copy number variants















С



Figure 2



Figure 3









С



Figure 5



-2 -1 0 1

